For Investors

At Delix, we are paving the way in neuroplasticity research, and every day is an opportunity to change the lives of people living with neurological conditions.

Our scientific team is pioneering the development of third-generation, non-hallucinogenic neuroplastogens, and we have more than 2000 compounds in our portfolio with one Phase 2 ready asset, several preclinical assets advancing steadily towards clinic, and other programs swiftly following behind.

Our pipeline is built on a discovery platform that identifies novel compounds that are convenient and scalable and produce rapid and sustained therapeutic effects. Delix is revolutionizing the future of neurological therapies by redefining treatment approaches and advancing innovative solutions that promise to transform patient care.